バイオテクノロジーニュース
-
December 6 , 2019
8 Biopharma Trends to Watch in 2020
- According to the article “8 Biopharma Trends to Watch in 2020” published by Alex Philippidis on GEN（Genetic Engineering & Biotechnology News）, there are eight biopharma-related trends in the coming new year. Presidential election, mergers and acquisitions, gene therapy CDMOs, Alzheimer’s disease, venture capital deals, CRISPR legal wrangle, genome editing ad
詳しく見る -
December 1 , 2019
2019 report advancing health through innovation
- Happy New Year! The beginning of a new year is always a rewarding time for the many dedicated staff at the FDA's Center for Drug Evaluation and Research (CDER) who work on approving new drug therapies. We look back over the past year and see how the work we did came together to help patients in need — one of the main reasons why many of us, including me, hav
詳しく見る -
June 13 , 2019
Following CAR-T pioneer¬s' footsteps, Tessa launches China JV in $120M deal
- These days just about every biotech serious about global development — and not just commercialization — has a Chi-na strategy. Tessa Therapeutics, a Baylor associated outfit based out of Singapore, is no exception.
詳しく見る -
January 28 , 2019
Zai Lab nabs speedy China regulatory review for PARP drug Zejula
- Chinese regulatory officials are signaling that they’re ready to whisk Zejula through the regulatory process.
詳しく見る -
January 3 , 2019
2019 M&A starts with a bang as BMS and Celgene agree $74bn merger
- The pairing will create a company with annual sales north of $34 billion, behind Pfizer, Novartis and Roche in terms of 2017 prescription drug sales and ahead of Merck & Co and Johnson & Johnson. There’s also plenty of scope for cost-cutting – the two companies think they can find $2.5 billion in “synergies” by 2022.
詳しく見る